Biogen announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders, scheduled to take place on June 14, 2023. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting. Dorsa joined the Biogen Board in 2010.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
- Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone
- Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review
- FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
- Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration